Enhancing Efficiency and Safety in Upstream Biomanufacturing

The use of animal-free reagents in the upstream manufacturing of biologic drugs is a common standard in biomanufacturing, essential for enhancing consistency and safety.

Insulin has emerged as a key component in cell culture for biomanufacturing, improving a wide array of processes such as monoclonal antibody (mAb) production in CHO cells, virus production in various cell types, stem cell culture performance and production of viral vectors for gene therapy.

Another crucial element in cell-based vaccine production is trypsin, which is essential for virus expansion and activation of specific virus particles, notably in the case of influenza. However, the use of animal-derived trypsin carries the inherent risk of introducing adventitious contaminants, potentially leading to cell culture infection with serious consequences for both patients and production continuity.

The introduction of the enzyme TrypsiNNex® effectively addresses these safety and consistency concerns. As a high-purity, recombinantly produced, animal-free trypsin, the enzyme ensures a more robust production process, effectively reducing the risk of contamination.

Through a controlled production process, the enzyme maintains an inactive form until stabilization, which results in a high and consistent proportion of β-trypsin and makes it an ideal choice for virus-vaccine production, resulting in cost savings and improved efficiency.

In this webinar, the expert speakers will illustrate how both insulin and TrypsiNNex® significantly enhance the safety and efficiency of upstream biomanufacturing processes, thereby enhancing the overall efficiency of therapeutic biologics production. Furthermore, they will delve into how the implementation of reagents such as insulin plays a significant role in reducing overall upstream costs by increasing process efficiency. 

Register for this webinar today to explore how innovative animal-free reagents are transforming upstream biomanufacturing.

Speakers

Sara Bursomanno, PhD, Senior Global Product Manager, Novo Nordisk Pharmatech A/S

Sara Bursomanno is a seasoned expert in Cancer Biology with over a decade of experience in academic research. Having transitioned to the biopharmaceutical industry over six years ago, Sara has excelled as a Product Manager, focusing on the upstream manufacturing of biological drugs.

Her specialized knowledge in cell culture and protein production allows her to effectively bridge the gap between scientific research and practical industry applications.

Message Presenter

Marie-Louise Lunn, PhD, Senior Global Product Manager, Novo Nordisk Pharmatech A/S

Marie-Louise Lunn serves as the Global Product Manager at Novo Nordisk Pharmatech, specializing in enzymes for bio-processing. She holds a degree in Pharmacy and a PhD in Molecular Biology and Drug Discovery from the University of Copenhagen, Denmark.

Following her tenure as a postdoctoral researcher at the Salk Institute for Biological Studies in San Diego, USA, she moved into the life science industry in 2006. Leveraging her scientific expertise, she effectively communicates technical product insights and provides invaluable support to the field of biopharmaceutical development.

Message Presenter